Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cirrhosis (scarring of the liver) of any cause, confirmed by clinical assessment, imaging, or tissue sample.
- People who have an enlarged spleen that has caused a reduction in blood cell counts (a condition called hypersplenism).
- People who had no sign of a blood clot in the portal vein (the large vein supplying the liver) on ultrasound and CT scan before surgery.
- People who had their spleen removed by keyhole (laparoscopic) surgery at the trial centre.
- People who received specific blood-thinning or anti-clotting medications starting three days after surgery, as directed by the trial protocol.
- People who showed no sign of a portal vein blood clot on imaging scans between 6 and 12 months after surgery.
- People who went on to develop a portal vein blood clot after 12 months following surgery.
- People who have given their written agreement to take part in the study.
Who may not be able to join:
- People who have liver cancer or any other type of cancer.
- People who have a blood-clotting disorder unrelated to their liver disease.
- People who are currently taking oral contraceptives, blood thinners, or anti-platelet medications.
- People who have experienced bleeding related to high blood pressure in the portal vein.
- People whose liver disease has been rated as Child-Pugh Class C, indicating severe liver impairment (confirm with trial site).
- People with a recent history of stomach or intestinal ulcers.
- People who have previously had a bleeding stroke.
- People who are pregnant.
- People with high blood pressure that is not well controlled.
- People who have HIV infection.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dou-Sheng Bai, Clinical Medical College, Yangzhou University
Phone: +8651487373382
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of complete recanalization of portal vein thrombosis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.